@ededed (Late reply) Yes, monitoring closely. Right now, whatever the article speculates, we don't have phase 3 trials showing that it's safe to go off ADT with stage 4, but they're underway. In my case, the LIBERTAS trial covers *exactly* my situation: stage-4 castrate-sensitive prostate cancer being treated with ADT and Erleada (Apalutamide). We should have preliminary results this fall. Small-scale retrospective studies and "may be optimal" are intriguing, but I need a little more than that before making a potentially life-threatening decision. I very much hope that the article you shared ends up being validated in full trials.